2. Disease Areas
  3. Cancer Urogenital Disease
  4. Breast Cancer Prostate Cancer Urogenital Cancer
  5. Anticancer agent 303

Anticancer agent 303 is a selective, orally active anticancer agent belonging to the pyrazolopyridine derivatives. Anticancer agent 303 exhibits low cytotoxicity to healthy cells, with a selective window of approximately 2-fold between cancer cells and healthy cells. Anticancer agent 303 produces detectable systemic exposure in mice following intraperitoneal or oral administration. Anticancer agent 303 effectively inhibits the proliferation of prostate cancer and breast cancer cells.

For research use only. We do not sell to patients.

Anticancer agent 303

Anticancer agent 303 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Anticancer agent 303 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Anticancer agent 303 is a selective, orally active anticancer agent belonging to the pyrazolopyridine derivatives. Anticancer agent 303 exhibits low cytotoxicity to healthy cells, with a selective window of approximately 2-fold between cancer cells and healthy cells. Anticancer agent 303 produces detectable systemic exposure in mice following intraperitoneal or oral administration. Anticancer agent 303 effectively inhibits the proliferation of prostate cancer and breast cancer cells[1].

In Vitro

Anticancer agent 303 (compound 17) (5 μM; 72 h) inhibits the viability of PC-3, MCF-7 and HUVEC cells, with mean IC50 values of 4.8 μM, 3.9 μM and 8.7 μM, respectively[1].
Anticancer agent 303 (5 μM; 1-24 h) accumulates in PC-3 cells in a time-dependent manner, reaching a level of 245.8 ng/40,000 cells (104.5% of the initial administered dose) after 24 h of treatment at 5 μM[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anticancer agent 303 Related Antibodies

Cell Cytotoxicity Assay[1]

Cell Line: human prostate adenocarcinoma PC-3 cells
Concentration: 5 μM
Incubation Time: 72 h
Result: Reduced PC-3 cell viability to 36% relative to DMSO control.
Exhibited an average IC50 of 4.8 ± 0.9 μM.

Cell Cytotoxicity Assay[1]

Cell Line: human breast adenocarcinoma MCF-7 cells
Concentration: 5 μM
Incubation Time: 72 h
Result: Reduced MCF-7 cell viability to 33% relative to DMSO control.
Exhibited an average IC50 of 3.9 ± 0.9 μM.
Parmacokinetics
Species Dose Route Cmax Tmax T1/2 AUC0-t AUC0-∞ Bioavailability
Mice[1] 4 mg/kg i.p. 372.2 ng/mL 4.8 h 14.4 h 5847.1 ng·h/mL 8721.3 ng·h/mL /
Mice[1] 8 mg/kg p.o. 199.0 ng/mL 6.5 h 16.3 h 3338.0 ng·h/mL 5299.1 ng·h/mL 29.13 %
In Vivo

Anticancer agent 303 (compound 17) achieves systemic exposure in mice via intraperitoneal (i.p.) and oral (p.o.) administration. Intraperitoneal injection yields higher systemic exposure than oral administration, as indicated by increased Cmax and AUC, and has a shorter time to peak concentration (Tmax), while the elimination half-lives of the two administration routes are similar. In addition, the dose-normalized relative oral bioavailability of Anticancer agent 303 is 29.13%[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight

470.57

Formula

C27H30N6O2
SMILES

O=C(NC1=CC=CC=C1)NC2=CC(OCCNC3CCCCC3)=C4C(N(C5=CC=CC=C5)N=C4)=N2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Anticancer agent 303 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anticancer agent 303Anticancer agent303Anticancer agent-303Othershealthy cellsprostate cancerprostate cancer cellsHUVEC cellbreast cancermiceMCF-7 cellantiproliferative agentbreast cancer cellsPC-3 cellInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Anticancer agent 303
Cat. No.:
HY-181558
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.